Form 8-K - Current report:
SEC Accession No. 0001193125-25-338394
Filing Date
2025-12-31
Accepted
2025-12-31 17:07:04
Documents
12
Period of Report
2025-12-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d69806d8k.htm   iXBRL 8-K 23224
  Complete submission text file 0001193125-25-338394.txt   137321

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aldx-20251223.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20251223_lab.xml EX-101.LAB 17991
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20251223_pre.xml EX-101.PRE 11258
14 EXTRACTED XBRL INSTANCE DOCUMENT d69806d8k_htm.xml XML 3642
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 251617928
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)